VentriPoint Diagnostics ( (TSE:VPT) ) has shared an announcement.
Ventripoint Diagnostics has received FDA 510(k) clearance for its VMS+ 4.0 Automated Radiological Image Processing Software/System, marking a significant advancement in cardiac imaging technology. The VMS+ 4.0 introduces AI-assisted features and magnet-free sensors, allowing it to be used with patients who have cardiac pacemakers, a group previously unable to undergo MRI imaging. This development is expected to improve diagnostic capabilities and workflow efficiency, potentially reducing the need for MRI in cardiac assessments.
More about VentriPoint Diagnostics
Ventripoint Diagnostics Ltd. operates in the medical technology industry, focusing on developing advanced diagnostic tools for cardiac imaging. Their primary product, the VMS+ system, enhances echocardiography by providing MRI-level accuracy in cardiac measurements, particularly beneficial for patients with pacemakers.
YTD Price Performance: -29.17%
Average Trading Volume: 143,555
Technical Sentiment Consensus Rating: Buy
Current Market Cap: C$13.84M
For a thorough assessment of VPT stock, go to TipRanks’ Stock Analysis page.